Streetbeat News

GRI

GRI Bio, Inc.

https://www.gribio.com

Industry

Biotechnology

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Open

0.73

Mkt cap

2.3M

Volume

654K

High

0.90

P/E Ratio

0.01

52-wk high

106.29

Low

0.72

Div yield

N/A

52-wk low

0.30

GRI Bio presented promising data on GRI-0621, a drug that may reduce inflammation, type 1 cytokines, and hepatic fibrosis in idiopathic pulmonary fibrosis (IPF). This was showcased at the 8th Annual Antifibrotic Drug Development Summit.

Portfolio Pulse from

November 21, 2024 | 2:00 pm

GRI Bio has reported its third quarter 2024 financial results, highlighting $13.9 million in gross proceeds raised since the start of 2024. This funding extends their cash runway into mid-Q1 2025, supporting the ongoing Phase 2a study of GRI-0621 for idiopathic pulmonary fibrosis.

Portfolio Pulse from

November 14, 2024 | 9:30 pm

Several healthcare stocks experienced significant price movements during Friday's intraday session. Notable gainers included Athira Pharma, ChromaDex, and Theriva Biologics, while Lexicon Pharmaceuticals and Myriad Genetics were among the biggest losers.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 4:36 pm

GRI Bio has raised $13.9 million in gross proceeds since the start of 2024, which is expected to extend its cash runway into mid-Q1 2025. This funding will support interim data from a Phase 2a study of GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The amount includes $0.8 million from a recent warrant exercise.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 12:33 pm

Several health care stocks experienced significant price movements during Wednesday's intraday session. CNS Pharma, Virax Biolabs Group, and Tevogen Bio Holdings were among the top gainers, while Alto Neuroscience and Silexion Therapeutics saw notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 4:31 pm

Several healthcare stocks experienced significant price movements during Tuesday's intraday session. Ensysce Biosciences, ENDRA Life Sciences, and Genprex saw substantial gains, while IN8bio, GRI Bio, and Voyager Therapeutics faced notable declines.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 4:31 pm

U.S. stocks fell with the Dow Jones down over 150 points. General Motors (GM) reported strong Q3 results, beating earnings and sales expectations, and raised its 2024 EPS guidance. Several biotech stocks saw significant price movements, with Genprex and Ensysce Biosciences surging, while GRI Bio and others declined.

Portfolio Pulse from Avi Kapoor

October 22, 2024 | 2:03 pm

In Tuesday's pre-market session, several health care stocks experienced significant movements. Ensysce Biosciences and Genprex saw substantial gains, while GRI Bio and Sensei Biotherapeutics faced notable declines. Medpace Holdings also declined following its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 12:07 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Ensysce Biosciences and Genprex saw substantial gains, while GRI Bio and Sensei Biotherapeutics faced notable declines. Medpace Holdings also saw a decrease following its Q3 earnings report.

Portfolio Pulse from Benzinga Insights

October 22, 2024 | 12:07 pm

iRhythm Technologies shares surged over 20% in pre-market trading following FDA clearance for its Zio AT device. Other notable pre-market movers include Genprex, SRM Entertainment, and TC Biopharm, with significant gains, while companies like IN8bio and DMC Global saw declines.

Portfolio Pulse from Avi Kapoor

October 22, 2024 | 11:06 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.